Treace Medical Concepts (NASDAQ:TMCI) Issues Quarterly Earnings Results

Key Points

• Treace Medical Concepts reported quarterly EPS of ($0.28), topping estimates, and revenue of $47.2 million, also ahead of expectations. However, the company still posted a net loss and negative margins.
• Management reaffirmed full-year 2026 guidance for revenue of $202 million to $212 million and an adjusted EBITDA loss of $4 million to $6 million. It also expects cash usage to decline by roughly 50% versus 2025.
• Early adoption of new product launches is improving, with more Lapiplasty surgeons using at least one of the new bunion systems and some new surgeons moving on to Lapiplasty as well. Treace says upcoming launches like SuperBite, SpeedXM, and Lapiplasty Lightning could expand its addressable market by about $300 million.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03, FiscalAI reports. Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 59.91%. The business had revenue of $47.20 million during the quarter, compared to analyst estimates of $45.96 million.

Here are the key takeaways from Treace Medical Concepts' conference call:

• Q1 revenue was $47.2 million, down ~10% year‑over‑year, with a net loss of $18.0 million and an adjusted EBITDA loss of $5.5 million, driven by lower bunion kit volumes and a shift toward lower‑priced products.
• Management reaffirmed full‑year 2026 guidance of $202–$212M in revenue (‑5% to 0% vs. 2025) and expects adjusted EBITDA loss of $4–$6M, while targeting a roughly 50% reduction in cash usage versus 2025.
• Commercial traction is building for the 2025 product launches — about 35% of Lapiplasty surgeons have adopted at least one of the three new bunion systems (up from 25% in Q4), and ~30% of new surgeons who started with those systems have also used Lapiplasty, indicating early pull‑through.
• The product roadmap is expanding — full commercialization of SuperBite and SpeedXM is expected in Q3 and Lapiplasty Lightning later this year, collectively increasing the addressable market by roughly $300M and opening access to higher‑ASP midfoot and hindfoot procedures.
• Management noted persistent macro pressure on elective procedures and an ASP/mix headwind from rapid adoption of lower‑priced MIS products that pressured top‑line results, though they expect these dynamics to abate in the back half and for growth to return in Q4.

Treace Medical Concepts Trading Up 4.7%

Shares of Treace Medical Concepts stock traded up $0.09 during trading on Friday, reaching $2.01. 763,851 shares of the stock were exchanged, compared to its average volume of 780,081. The company has a quick ratio of 3.13, a current ratio of 4.31 and a debt-to-equity ratio of 0.64. The stock's fifty day moving average is $1.62 and its 200 day moving average is $2.65. The firm has a market cap of $130.21 million, a price-to-earnings ratio of -2.14 and a beta of 1.10. Treace Medical Concepts has a 1 year low of $1.17 and a 1 year high of $7.78.

Analyst Ratings Changes

TMCI has been the subject of several analyst reports. Wall Street Zen upgraded shares of Treace Medical Concepts from a "strong sell" rating to a "sell" rating in a research report on Monday, April 27th. Weiss Ratings restated a "sell (e+)" rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. Finally, Lake Street Capital dropped their target price on shares of Treace Medical Concepts from $7.50 to $7.00 and set a "buy" rating for the company in a report on Monday, March 2nd. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus price target of $4.77.

Institutional Trading of Treace Medical Concepts

A number of institutional investors have recently modified their holdings of the company. Armistice Capital LLC boosted its holdings in shares of Treace Medical Concepts by 0.9% during the third quarter. Armistice Capital LLC now owns 6,316,000 shares of the company's stock worth $42,380,000 after purchasing an additional 56,000 shares during the period. Millennium Management LLC boosted its holdings in shares of Treace Medical Concepts by 12.7% during the third quarter. Millennium Management LLC now owns 1,710,140 shares of the company's stock worth $11,475,000 after purchasing an additional 192,929 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Treace Medical Concepts by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 847,675 shares of the company's stock worth $5,688,000 after purchasing an additional 3,677 shares during the period. Kotler Kevin bought a new position in Treace Medical Concepts in the fourth quarter worth about $1,162,000. Finally, Dimensional Fund Advisors LP raised its stake in Treace Medical Concepts by 11.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 273,376 shares of the company's stock worth $670,000 after buying an additional 28,912 shares in the last quarter. 84.08% of the stock is currently owned by hedge funds and other institutional investors.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company's flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.